LY503430
| Code | Size | Price |
|---|
| TAR-T27959-5mg | 5mg | £1,332.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T27959-50mg | 50mg | £2,625.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T27959-100mg | 100mg | £3,524.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
LY503430 is a AMPA receptor potentiator with oral activity. LY503430 has both nootropic and neuroprotective effects, reducing brain damage caused by 6-hydroxydopamine or MPTP.
CAS:
625820-83-9
Formula:
C20H25FN2O3S
Molecular Weight:
392.49
Purity:
0.98
SMILES:
CNC(=O)c1ccc(cc1)-c1ccc(cc1)[C@@](C)(F)CNS(=O)(=O)C(C)C
References
1. Duthion B, Gomez Pardo D, Cossy J. Enantioselective synthesis of ?-fluoroamines from ?-amino alcohols: application to the synthesis of LY503430. Org Lett. 2010 Oct 15;12(20):4620-3. doi: 10.1021/ol1019579. PubMed PMID: 20849096.
2. O'Neill MJ, Witkin JM. AMPA receptor potentiators: application for depression and Parkinson's disease. Curr Drug Targets. 2007 May;8(5):603-20. Review. PubMed PMID: 17504104.
3. Ryder JW, Falcone JF, Manro JR, Svensson KA, Merchant KM. Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. J Pharmacol Exp Ther. 2006 Oct;319(1):293-8. PubMed PMID: 16803862.
4. O'Neill MJ, Murray TK, Clay MP, Lindstrom T, Yang CR, Nisenbaum ES. LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease. CNS Drug Rev. 2005 Spring;11(1):77-96. Review. PubMed PMID: 15867954.